2017
DOI: 10.1016/s0016-5085(17)33711-3
|View full text |Cite
|
Sign up to set email alerts
|

Prospective Analysis of Discordant Results Between Fibromax® and Fibroscan® in Patients with HCV Compensated Liver Cirrhosis before 3D Antiviral Therapy Initiation

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles